<DOC>
	<DOCNO>NCT00892359</DOCNO>
	<brief_summary>The purpose trial study pharmacokinetics anidulafungin continuous venovenous hemofiltration . Background : Anidulafungin cyclic lipopeptide antifungal agent echinocandin class . Members class antifungal agent know inhibit synthesis glucan polymer fungal cell wall . The spectrum activity anidulafungin include Candida ( specie , include strain resistant fluconazole ) , Aspergillus , Pneumocystis . In intensive care patient continuous venovenous haemodiafiltration ( CVVHF ) well-established extracorporal renal replacement therapy high clearance rate . Pharmacokinetic study antifungal agent critically ill patient treat CVVHF rare . No data anidulafungin CVVHF available although intensive care patient perfect candidate anidulafungin treatment due high risk profile systemic fungal infection . Study objective : The study conduct investigate pharmacokinetics anidulafungin CVVHF critically ill patient . Study design : open , 1 arm Study population : 10 critically ill adult patient administer ICU acute renal failure suspect proven fungal infection . Treatment/Dosage/Route : On first day 200 mg anidulafungin administer intravenously 3 hour ( load dose ) . The following day 100 mg anidulafungin administer intravenously 1.5 hour . Main outcome variable : The following pharmacokinetic parameter determine : area curve ( AUC ) , half-live ( t1/2 ) , maximum plasma concentration ( Cmax ) elimination fraction . Methods : High pressure liquid chromatography ( HPLC ) use determine anidulafungin concentration .</brief_summary>
	<brief_title>Anidulafungin During Continuous Venovenous Hemofiltration ( CVVHF )</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Age 19 70 year Suspected proven infection require parenteral antifungal therapy . Continuous venovenous hemofiltration acute renal failure . Known history hypersensitivity echinocandins . An expected survival less three day . Known alcohol dependency , epilepsy , pregnancy liver failure . Neutropenic patient</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>renal replacement therapy</keyword>
	<keyword>hemofiltration</keyword>
	<keyword>anidulafungin</keyword>
</DOC>